Fig. 6: Pembrolizumab-responsive PBMCs in the No pCR cohort. | British Journal of Cancer

Fig. 6: Pembrolizumab-responsive PBMCs in the No pCR cohort.

From: Alterations in immune cell phenotype and cytotoxic capacity in HER2+ breast cancer patients receiving HER2-targeted neo-adjuvant therapy

Fig. 6

Trastuzumab ADCC levels with and without pembrolizumab against SKBR3 cells using pre-treatment patient PBMCs from a pCR (n = 7) and b No pCR (n = 14) cohorts. Bars represent the average of three technical replicates +/− Std. Dev. c Comparison of pre- and post-treatment CD56+CD16+ levels by treatment response. d Comparison of pre- and post-treatment CD14+CD16+ levels by treatment response. e PD-1+CD56 +CD16+/− and PD-1+CD14+CD16+/− as a percentage of CD45+ immune cells or subset total (CD56+ or CD14+) +/− Std. Dev. based on assay response in (a) and (b). f Trastuzumab ADCC levels with and without pembrolizumab against SKBR3 cells using post-treatment patient PBMCs from the No pCR patient cohort. Average of three technical replicates +/− Std. Dev. g Average pre-treatment infiltrating lymphocyte levels in tumour, stroma and combined for patients whose pre-treatment PBMC samples responded to pembrolizumab in (b) (n = 6) versus patient samples that did not respond to pembrolizumab in (a) (n = 7) +/− Std. Dev. Unpaired or paired (c, d) Student’s t tests were used to determine statistical significance, *p < 0.05.

Back to article page